Pricing Log in Create free account
Friday 6 November 2026 Export ARGX’s income statement to Excel — free account

argenex SE

ARGX Healthcare Biotechnology

argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.

Revenue
+52.1%
EPS
+43.9%
Free cash flow
+537.5%

Quarter to September 2026, against a year earlier

909.66 14.89 +1.66%
Market cap
$56.3B
P/E
29.8×
Fwd P/E
30.1×
Dividend yield
—
F-score
5/9
Altman Z
24.36
Beneish M
−1.51
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

argenex SE (ARGX) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, argenex SE (ARGX) trades at a EV/Sales of 8.9×. Over the past ten years it has ranged from 0.0× (March 2020) to 165× (February 2021); the current reading is higher than 31% of that period. That is in line with the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 11.3× (27.86%)
FY2024 15.7× 0.80%
FY2023 15.6× (64.53%)
FY2022 43.9× 81.24%
FY2021 24.2× (80.25%)
FY2020 123× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 9.5× (6.23%)
Jun 2026 10.2× 15.66%
Mar 2026 8.8× (22.22%)
Dec 2025 11.3× (3.43%)
25 more quarters

Against its own ten years

Low 0.0× High 165×
Ten-year median 14.8×
Current reading's percentile 1

EV/Sales against peers

Company EV/Sales
INCY Incyte Corporation compare 3.4×
REGN Regeneron Pharmaceuticals, Inc. compare 5.1×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 5.9×
GMAB Genmab A/S Sponsored ADR compare 8.7×
ARGX argenex SE 8.9×
RPRX Royalty Pharma PLC compare 14.6×
MRNA Moderna, Inc. compare 41.1×
RVMD Revolution Medicines, Inc. compare 172×
ROIV Roivant Sciences Ltd. compare 3,061×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ARGX